<DOC>
	<DOCNO>NCT00815659</DOCNO>
	<brief_summary>The primary objective evaluate efficacy rosuvastatin therapy plasma lipid profile ( Low Density Lipoprotein ( LDL ) , High-Density Lipoprotein ( HDL ) , total cholesterol , triglyceride ) patient metabolic syndrome .</brief_summary>
	<brief_title>Effect Crestor ( Rosuvastatin ) Lipid Levels Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>metabolic syndrome ( accord National Cholesterol Education Program ( NCEP ) Adenosine triphosphate ( ATP ) Ill criterion ) LDLCholesterol &gt; 130mg/dl HDLCholesterol &lt; 40mg/dl male &lt; 50mg/dl female Triglycerides &lt; 400 mg/dl With concomitant coronary disease Currently statin therapy previously treat statin within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>plasma lipid profile</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>